Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals, Inc.（ARMP）股东结构
基于 13F 申报与流通股数据，展示机构、内部人与公众持股结构；下方为前十大机构、机构动向与内部人交易。
SEC 13F · FMP · ARMP · 截至 2025年9月30日
股东结构概览
28
机构持有人数
▼ 1 vs Q2
$2.27M
机构持仓总市值
▲ $875,414 vs Q2
36.71M
总流通股
freeFloat 30.84%
759,749
13F 申报持股数
▲ 24,505 vs Q2
机构持仓% = 13F 持股数 ÷ 总流通股。内部人% = 100 − 自由流通率。散户% = 自由流通率 − 机构%。数据来源：FMP /symbol-positions-summary + /shares-float + SEC EDGAR。
前10大机构持仓
ARMP 最大股东 · 机构持仓
Q3 2025 · SEC 13F
显示前 10 家
| 机构 | 持股数 | 占比 | 权重 | 市值 | 申报日 | 变动 |
|---|---|---|---|---|---|---|
VANGUARD GROUP INC biological products, (no diagnostic substances) | 297.0K | 82.07% | 82.07% | $885.17M | Nov 7, 2025 | ▲ 37.0K |
GEODE CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 104.5K | 28.89% | 28.89% | $311.64M | Nov 12, 2025 | — held |
EDGEWOOD MANAGEMENT LLC biological products, (no diagnostic substances) | 100.0K | 27.63% | 27.63% | $298.00M | Nov 12, 2025 | — held |
BRIDGEWAY CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 44.7K | 12.35% | 12.35% | $133.15M | Nov 14, 2025 | — held |
RENAISSANCE TECHNOLOGIES LLC biological products, (no diagnostic substances) | 41.3K | 11.41% | 11.41% | $123.06M | Nov 13, 2025 | ▲ 2.4K |
STATE STREET CORP biological products, (no diagnostic substances) | 40.3K | 11.13% | 11.13% | $120.09M | Nov 14, 2025 | — held |
SEACREST WEALTH MANAGEMENT, LLC biological products, (no diagnostic substances) | 35.0K | 9.66% | 9.66% | $112.55M | Nov 13, 2025 | — held |
GSB WEALTH MANAGEMENT, LLC biological products, (no diagnostic substances) | 30.0K | 8.29% | 8.29% | $89.40M | Oct 21, 2025 | — held |
BLACKROCK, INC. biological products, (no diagnostic substances) | 26.7K | 7.37% | 7.37% | $79.46M | Nov 12, 2025 | ▲ 748 |
NORTHERN TRUST CORP biological products, (no diagnostic substances) | 19.3K | 5.32% | 5.32% | $57.43M | Nov 14, 2025 | — held |
数据来源：SEC 13F 申报文件。变动标识：isNew / isSoldOut / changeInSharesNumber。
机构仓位变动
Q3 2025 对比上季度
Q3 2025
4
增持
+40.2K 股2
新建仓
首次建仓3
减持
−1.6K 股3
清仓
完全退出净股数变化（前50家）
+38.6K
+40.2K / −1.6K
净新增持仓人
+0
新建 2 个 / 退出 3 个
基于前50家最大机构持仓统计，全市场实际数量可能不同。
内幕交易买卖情绪
ARMP 内幕交易记录
数据来源：SEC Form 4
9
买入笔数
0
卖出笔数
0.00
买卖比
$0M
卖出总金额
最近内幕交易记录
最近10条 · 仅普通股
| 姓名 · 职位 | 日期 | 类型 | 股数 | 价格 | 金额 | 交易后持股 | 申报 |
|---|---|---|---|---|---|---|---|
Gilmer Daniel B. director | Apr 24, 2026 | Award | 51,280 | $12.92 | $662.5K | 51.3K | Form 4 ↗ |
Kyme Pierre Chief Business Officer | Mar 14, 2026 | Tax Withhold | 1,030 | $10.54 | $10.9K | 9.5K | Form 4 ↗ |
Birx Deborah Chief Executive Officer | Mar 14, 2026 | Tax Withhold | 4,919 | $10.54 | $51.8K | 212.5K | Form 4 ↗ |
Kramer Robin director | Mar 9, 2026 | Award | 25,640 | $11.61 | $297.7K | 25.6K | Form 4 ↗ |
Kyme Pierre Chief Business Officer | Mar 9, 2026 | Award | 183,142 | $11.61 | $2.13M | 183.1K | Form 4 ↗ |
House David Duane SVP, Finance, and PFO | Mar 9, 2026 | Award | 109,885 | $11.61 | $1.28M | 109.9K | Form 4 ↗ |
PATTI JOSEPH M director | Mar 9, 2026 | Award | 25,640 | $11.61 | $297.7K | 25.6K | Form 4 ↗ |
Peterson Todd C. director | Mar 9, 2026 | Award | 25,640 | $11.61 | $297.7K | 25.6K | Form 4 ↗ |
Odysseas Kostas D director | Mar 9, 2026 | Award | 25,640 | $11.61 | $297.7K | 25.6K | Form 4 ↗ |
Birx Deborah Chief Executive Officer | Mar 9, 2026 | Award | 421,226 | $11.61 | $4.89M | 421.2K | Form 4 ↗ |
数据来源：SEC Form 4。买卖方向：acquisitionOrDisposition A=买入，D=卖出。已排除 RSU 归属（M-Exempt）。
关于机构与内部人持股结构
Armata Pharmaceuticals, Inc.（ARMP）主要由机构投资者持有，机构持股比例约为 2.1%。公司内部人员持股约 69.16%，散户及公众持股约占剩余的 28.77%。
Armata Pharmaceuticals, Inc. 最大机构股东为 VANGUARD GROUP INC，截至 September 30, 2025 持有约 297,038 股，占总流通股的 82.07%。
目前共有 28 家机构持有 ARMP 股票，合计持仓市值约 $2,272,532，数据来源为最新 SEC 13F 申报。
常见问题
ARMP ownershipArmata Pharmaceuticals, Inc.（ARMP）主要由机构投资者持有，机构持股约 2.1%。最大股东为 VANGUARD GROUP INC，持股比例 82.07%。内部人员持股约 69.16%。数据来源 SEC Form 13F，截至 September 30, 2025。